| 1. |
Chow SC, Chang M. Adaptive design methods in clinical trials-a review. Orphanet Journal of Rare Diseases, 2008, 3(11): 1-13.
|
| 2. |
Brahmachari B, Bhatt A. Adaptive design-An innovative tool in drug development. Indian J Med Res, 2011, 133(3): 243-245.
|
| 3. |
Cirulli J, McMillian WD, Saba M, et al. Adaptive trial design: its growing role in clinical research and implications for pharmacists. Am J Health Syst Pharm, 2011, 68(9): 807-813.
|
| 4. |
Emerson SC, Rudser KD, Emerson SS. Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings. Stat Med, 2011, 30(11): 1199-1217.
|
| 5. |
Wang SJ, James Hung HM, O’Neill RT. Impacts on type I error rate with inappropriate use of learn and confirm in confirmatory adaptive design trials. Biom J, 2010, 52(6): 798-810.
|
| 6. |
Brass EP, Cooper LT, Morgan RE, et al. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Asthma, 2010, 47(10): 1078-1084.
|
| 7. |
Lewis RJ, Connor JT, Teerlink JR, et al. Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials, 2011, 12(134): 1-9.
|
| 8. |
Cheung K, Kaufmann P. Efficiency perspectives on adaptive designs in stroke clinical trials. Stroke, 2011, 42(10): 2990-2994.
|
| 9. |
Scher HI, Nasso SF, Rubin EH, et al. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.Clin Cancer Res, 2011, 17(21): 6634-6640.
|
| 10. |
Chataway J, Nicholas R, Todd S, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler, 2011, 17(1): 81-88.
|
| 11. |
Høivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia, 2010, 30(12): 1458-1467.
|
| 12. |
Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol, 2011, 9(4): 199-207.
|
| 13. |
Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia, 2011, 31(6): 712-722.
|
| 14. |
Di Scala L, Glimm E. Time-to-event analysis with treatment arm selection at interim. Stat Med, 2011, 30(26): 3067-3081.
|
| 15. |
Li W, Fu H. Bayesian optimal adaptive designs for delayed-response dose-finding studies. J Biopharm Stat, 2011, 21(5): 888-901.
|
| 16. |
Eickhoff JC, Kim K, Beach J, et al. A Bayesian adaptive design with biomarkers for targeted therapies. Clin Trials, 2010, 7(5): 546-556.
|
| 17. |
Cock HR, ESETT Group. Established status epilepticus treatment trial (ESETT). Epilepsia, 2011, 52(8): 50-52.
|
| 18. |
王素珍. 自適應設計中樣本量調整問題的研究及web實現. 西安:第四軍醫大學, 2008.
|
| 19. |
任建玲. 適應性設計方法在抗腫瘤藥物劑量探索臨床試驗中的研究. 上海: 第二軍醫大學, 2009.
|
| 20. |
趙超. 臨床適應性設計與藥物評價的考慮. 中國臨床藥理學與治療學, 2008, 13(1): 1-5.
|
| 21. |
Kuznetsova OM, Tymofyeyev Y. Brick tunnel randomization for unequal allocation to two or more treatment groups. Stat Med, 2011, 30(8): 812-824.
|
| 22. |
Response-adaptive randomization for clinical trials with adjustment for covariateImbalance. Stat Med, 2010, 29(17): 1761-1768.
|
| 23. |
Chevret S. Bayesian adaptive clinical trials: a dream for statisticians only? Stat Med, 2011, 6(12): 106.
|
| 24. |
王素珍, 夏結來, 劉典恩. 藥物臨床試驗設計的倫理思考. 臨床決策與倫理, 2008, 29(8): 70-73.
|
| 25. |
Fu H, Wang Y, Liu J, et al. Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model. Stat Med, 2012, 7(7): 325-330.
|
| 26. |
Chow SC, Corey R. Benefits, Challenges and obstacles of adaptive clinical trial designs. Orphanet J Rare Dis, 2011, 6(1): 79.
|
1/5
微信公眾號